Medis

Medis specializes in out-licensing high-quality generic pharmaceuticals to third-party pharmaceutical companies. Established in 1985, we offer a broad portfolio of 185 generic pharmaceutical products, mainly in the form of tablets, capsules and injections. Our portfolio includes a growing range of specialist oncology products and product formulations, predominantly solid oral dosages. We develop these products in house and provide our customers with the necessary regulatory support. In fact, we have a proven track record in securing regulatory approval prior to patent expiries, and have supported our customers in obtaining marketing authorizations in over 140 countries. Medis has full backing from our parent company, Teva Pharmaceutical Industries Ltd. We draw on their development and manufacturing capabilities, and their team of in-house experts. At the same time, our focus on technical excellence and compliance extends to our treatment of our customers confidential information. At Medis, we pride ourselves on our longevity and our loyalty. For over 35 years, we have built strong and lasting relationships with our customers, and we are confident that these relationships will only be enhanced going forward.